LENZ Therapeutics (LENZ) Retained Earnings (2020 - 2026)
LENZ Therapeutics (LENZ) reported Retained Earnings of -$268.6 million for Q1 2026, down 218497.56% year-over-year from N/an in Q1 2025, and down 18.27% quarter-over-quarter from -$227.1 million in Q4 2025.
LENZ Therapeutics (LENZ) Retained Earnings (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 7 years of Retained Earnings data on file, last reported at -$268.6 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$268.6 million, down 218497.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$268.6 million (down 218497.56% YoY), and the FY2025 annual result was -$227.1 million, down 56.63% from the prior year.
- Retained Earnings declined to -$268.6 million in Q1 2026 per LENZ's latest filing, from -$227.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $123000.0 in Q1 2025 and troughed at -$344.1 million in Q3 2023.
- A 5-year average of -$164.6 million and a median of -$174.5 million in 2025 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings sank 2417000.0% in 2024, then jumped 12400.0% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$242.4 million in 2022, then soared by 100.0% to $6000.0 in 2023, then slumped by 2417000.0% to -$145.0 million in 2024, then tumbled by 56.63% to -$227.1 million in 2025, then declined by 18.27% to -$268.6 million in 2026.
- Business Quant data shows LENZ's Retained Earnings at -$268.6 million in Q1 2026, -$227.1 million in Q4 2025, and -$191.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | LENZ Therapeutics | 192.19 Mn | 192.19 Mn | 825,000.00 | -268.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268.63 Mn |
| Dec 31, 2025 | -227.14 Mn |
| Sep 30, 2025 | -191.20 Mn |
| Jun 30, 2025 | -174.55 Mn |
| Mar 31, 2025 | 123,000.00 |
| Dec 31, 2024 | -145.01 Mn |
| Sep 30, 2024 | -132.40 Mn |
| Jun 30, 2024 | -122.15 Mn |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | -344.14 Mn |
| Jun 30, 2023 | -321.65 Mn |
| Mar 31, 2023 | -266.34 Mn |
| Dec 31, 2022 | -242.40 Mn |
| Sep 30, 2022 | -1.60 Mn |
| Jun 30, 2022 | -193.12 Mn |
| Mar 31, 2022 | -167.19 Mn |
| Sep 30, 2021 | -122.42 Mn |
| Jun 30, 2021 | -107.80 Mn |
| Dec 31, 2020 | -70.59 Mn |